Oo¢usignEn%elope ID." 8fK8ED2F.F7BMgfUo37￿98l IC68D562
Registered number: 12099857
Charity number: 1200765
TREAT-NMD Alliance Ltd
Annual report
31 December 2025
IDIIIIIII
*AFBN¢A)YYt
*186
COMPANIES HOUSE

Do¢u519Th Envelope ID.. BoC8ED2F*78M￿?E98l1C6O1Afj2
TREAT-NMD Alliance Ltd
Contents
Page
Referen￿ and administrative detsils
Trustees. report
Truslees, responsibilities statement
Independent auditors. report on the finanaal statement$ lo the members of TREAT-NMD
Alliance
10-13
Consolidated statement of financial aclivil
14
Consolidated balance sheet
15
Charity balance sheet
16
Cor>solidated ststemenl of cash flNs
17
Note5 to the financial slalements
18-35

DouJ5¥Jn Envelope10.. &￿8E02F￿2￿￿￿037Es811c68￿2
TREAT-NMD Alliance Ltd
Reference and administrative details
Period ended 31 December 2025
Trustees
Prof Volker Wilhelm Slraub
Dr James Joseph Dvwling (resigned 2 June 2025)
Prof and t>ean Kanneboyina Nagaraju
Dr Kathryn Rae Wagner {aprknnted 2 June 20251
Company registered
number
12099857
Charity registered
number
1200765
Reglsterèd offl¢e
CIO Womble Bond Diekinson (UK) LLP
The Spark. Oraymans Way
Newcastle Helrx
Neweasue upon Tyne. Englarh
NE4 5DE
Company secretary
David Allison
Chief exKudvg officer
David Atlison
Independent auditors
UNW LLP
Chartered Accountants
Cityg*e
Sl James. Boulevard
Newcastte upon Tyne
NE14JE
Page 1

OorJJsiqn ErNelope ID.. BOc8ED2F-F7B>8KA4o37￿9￿11C880562
TREAT.NMD Alliance Ltd
Trustee$, report
Period ended 31 December 2025
The trustees present their annual report together %Mih the audrted ffinanoal statements of the chaTily for the 17
month period 011 August 2024 to 31 December 2025. The annual report serves the purposes of both a Iruslees.
report and a directors, report under company law. The trustees confirm that the annual report and financial
statements of the chantable company comply wrth the current slalutory requirements, the requirements of the
charitable company's govefning document and the provisions of the Statement of Recommended Practice
{SORP} applicable to charrt￿S preparing their accounts in accordance wrth the Financial Reporting Standard
applicable in the UK and Republic of Ireland IFRS102} (effectrve 1 January 2019).
Since the group and the charty qualrfy as small under seclh)n 383 of the Crynpanies Act 2006, the group
strategi¢ report required of medium and large companEs under the Companie$ Act 2006 (Strategic Report and
D1￿Clor$, Report) Regulations 2013 has been omrtled.
Oblectivos and acllvltles
Policies and objectives
The charitys object$ are speCif￿ty restricted lo the folb)wing."
TREAT-NMD Alliance Ltd exists for the public benefft lo advance the health of the public arKJ, ancillary lo this. to
advance the education of the public, principalty, bLrt not excluswety, by.
promoting research into new Medic￿ thefapie5 for the treatment of neuromuscular and other rare
diseases provided that the useful resutts of such research are disseminated to the public al large.,
educating medical practrtioners. scientists and other profess￿n81$ In the care and t￿atment of persons
with neuromuscular and other rare diseases"
supporting and thereby relievir¥J the needs of and improving the quality of lives of persons with
neuromuscular and olher rare diseases land their families and carers) by educating about and promoting
aceessibilty lo treatment or by such other means as the trusiees shall see fft", and
raising awareness of li￿lUdIng devebpments in treatment options for) neuromuscular and other rare
disease5.
Strategies for achieving objeclives
The strategies for achieving the group objects can be summarised by the TREAT-NMD Aims..
Inform. Connect, Advance
The activities of the group can be clustered around and summarwl by each of these words.
The actiwlies of TREAT-NMD Allan￿ Ltd centre around the provision of education and training events.
TREAT-NMD SeThices Ltd aclNil*s infomi healthcare professionals as to the impact neuromuscular diseases
have on patients and their families. h¢)w best lo diagnose Ihe5e di5e8ses. the current best advice regarding
pathwayB of Care and provide details of emerging treatments. Famity Guides help newty diagnosed patients to
understand Iheir disease and what support is available.
TREAT-NMD SeThKes Ltd provKles a range of wnmercial Ser¥￿S a¢r05S the drug devebpmenl pipeline that
infom, conneet and advance treatmenls to patients by derisking Clinical trials and sharing best practice,
providing data and running projects lo support studies, cFinieal trial design, and post authorisalion long term
follow up. and by running sponsofed events. most notabty the biennial TREAT￿MD Conference that brings
patients, researchers. xademi¢s and industry together to share information, connect stakeholders and
Communrties, and to raise awareness of issues and emerging solutions.
Hawng given due consxleralion to the Charty Comrnission guidan￿ relatiru to publi¢ benefit. the Iruslees are
satisfied Ihal the actiwknes of the TRBAT-NMD group continue to deliver sub$lantial benefits in line with the
chartys objects.
Page 2

DorJJ$wJn Env￿optI0.. gOC8ED2F.F78MU8037.E9811C68D562
TREAT-NMD Alliance Ltd
Trustees, report Icontinued)
Period ended 31 December 2025
Achlevements and performance
Main achievements
To best progress the aims and objectives of the TREA T-NMD Global Nelwork rt was determined that, in addition
to the commercial trading entity TREAT-NMD Services Ltd. a TREAT￿MD group structure would be
established wrth a UK regisleied charity, TREAT-NMD AIIK4n¢e Ltd.
In addition to establishing a Board of Trustees of TREAT-NMD Allian￿ Ltd from the Gbbal Netsvork, an
advis¢yy commtttee- NMDAC was established to provide insight as lo global NMD priorities.
A key achievement of this year saw TREAT4IMD SeNices Ltd progress in the Grant Agreement lo deliver key
milestones of the PaLaDln Project. Thi$ sees TREAT-NMD as the Scienlffic Coordinator for a 9-partner
consortium with funding coming from the European CommissK)n IIHI Call 31 and Innovate UK (Grant Guarantee
Schemel. In 2025 the General Assembly ￿￿$ hekl in Rome. required to 8ngage patients and clinicians in the
development of the Inlera¢tium.
The Global Registry Nebvork held its Annual Curators Meeting in Milan in February 2025 and this saw more
than 40 registry curators gather lo discus5 how best lo contribute to drug develcpment through dats provision
wth an emphasis on dats qualty. The data qualty management tool devebped by TREAT-NMD was
demonstrated and received excel￿nI feedback. Input into key deliverables of the PaLaDln project were
discussed wth the global curators for input and verification of design processes.
To further estsblish ccfftct foundations. the Compliance team have led the efforts lo gain IS027001
continued acefeditalK>n. This team will support the growng activty of TREAT-NMD group in data provision and
help establish the necessary qualrty framework.
The Data and Scientific Projeets teams have been working wrth Key Opinion Leaders to leverage the Global
Registry Network data to SLtpport a Trmde range of data prwects al various stages of the drug development
pipeline.
The use of the nefv￿rt(. its govemanee. the data, the technology and the qualty framework were described lo
the European Med￿lneS Agency IEMA) in the TREAT-NMD Services Ltd submission to the E￿ Qualification
process undertaken during last year and this remains an area of ongoing pro9￿SS and focus.
The status of potential NMD treatments is maturing and this has led to multiple authorisalions by the regulator
and a greater number of trealments advancing towards aulh0risal￿}n. This is resurting in a growing demand for
high quality, patient level Real World Data to SLtpport applications and their long term follthv up. This is a real
challenge globally for providers of Real Worfd Ev￿ence IRWEI and the TR&4T-NMD group are no exceptions.
Overseeing a range of Data Qualty Improvement Inrtiatives i% the top priority for TGDOC - The TREAT-NMD
Global Data Over5ighl COmrn￿ee. The PaLaDln Project wll see the delwery of updated datasets in
Facioscapulohumeral Muscular Dystrophy IFSHDI and Myotonic D￿trophY moving forwards.
A wide range of events were delNered by TREAT44MD throug1￿Ut the year I￿lUdi1￿￿ a LGMD Maste￿laSS in
Montreal March 2025, patient Becker Masterelass in September 2025. Duchenne Muscular Dystrophy IDMDI
and Spinal MusoJLryr Alrcphy ISMA) PAaslerclasses in Prague Juty 2025 as well as our Industry Day.
A range of educational pr¢¥ects have been pro9￿$sed wtyth the DMD Earty Diagnosis, and the LIM￿1rdle
Muscular Oystrophy {LGIAD) Famity Guide most notable.
Page 3

OocusigTh Env•knw ID. 8OC8ED2F-F7B>8￿A￿037￿9B11c68D
TREAT-NMD Alliance Ltd
Trustses, report (contlnued)
Period ended 31 December 2025
Achlevements and perfomiance Icontlnuedl
Plans for future periods
Having established the TREAT-NMD group slruclure, at the end of 2025 a Governanee Review was undertaken
with external advisors the re$uA of which has led to establishing Non Execulrve Board va￿ncieS which will be
add￿ssed in 2026.
Followng on from our successful to the European Commissb)n IHI Call 3. the PaLaDln Project needs to
move beyond estsblishing the govemance and funding lo devek)p the specffication for the central plattorm, the
Inleracb"um, and ensuring that the consortium partners actNities ale well aligned. The input of the Extemal
AdMscAy Board and the Ethics Board wll be fvndamental to ensuring that the key prIOr￿e$ are progressed.
An i￿reasing focus on Data wll align well vith the Regulalors. desire to rnake better use of Real-world
Data. This will see TREAT-NMD continue to develop technologtsl solutions to assist the g￿bal registry ne￿Ork
in continuous improvement arKI stronger links our growing online edvcatK)n offerings lo increase regulator
and industry assurance. Moving fO￿ardS. TREAT-NMD will be aiming to introduce a standard neuromuscular
disease dalasel to better addiess industy needs and to uttimatety gain EMA Qualification across a range of
diseases induding SMA, DMD and LGMD.
Strategic relal#)nships remain key lo TREAT-NMD. Although a Gk)bal nelwork. Ikke the pharmaceutical industry
8s a whole, TREAT-NMO'S emphasis has tradrtionally been in Europe and North America. Moving forwards, the
organisalion is keen to increase ils presence gktlally and to be more inclusive where ils support Can have
positive impad.
Financial review
Financial performance
The Group changed its &eounting reference date during the period. These financial statements therefore cover
an extended accounting peri¢xl of 17 months, from 1 August 2024 to 31 December 2025. aligning the Group's
repo￿.n9 cycle with the calendar year.
Because the current period spans 17 months. rt is not directy comparable with the preceding 12-month period.
and comparative figures should be read wth that in mind. To assist readers, an analysi$ of the resutt be￿n
the fv40 conslituenl peri￿$ is set out in Ta￿e 3.
Budget figures represent the budget approved by the Board for the full extended period. All fjgures ar9 Stated in
pounds sterling and rounded to the nearest pound. Figures in brackets denote negatwe amounts oi adverse
variances.
Overview of the result
The Group recorded total income of £3,094,584 and total expendrtuie of £3.104.880 for the 17-monlh period,
resulting in a net defKit 01 £10.296. This deficrt is ststed after charging exceptional costs of £11,907 and a
depreciation ¢haige of £3.201. Excluding these rtems. the Group's UnderI￿n9 operating result was a surplus of
£4.812. which is £4.723 ahead of the budgeted resuh of £89 (Break*venl-
The leadership team consider the Group to have perfoTrned broadly in line with budget al the operating level,
nO￿lth5tandpng a lower than budget income in lunding inccvne whith was subslanlialty offset by Ioy•ver direct
delivery costs.
Page 4

Doc￿51qn Enwlope ID.. B0C8ED2F￿7BwA￿O37￿g8l1￿DS62
TREAT-NMD Alliance Ltd
Trustees. report (continued)
Period ended 31 December 2025
Table l - Summary of f#)antial perfmffta￿ for the 17.month pernd ended 31 December 21Y25
Actual 11
month5
Budget
Variance
Varrance
Furthg incon
3,￿0,563
3A59,291
1372.7281
(JO.81
Interest rece￿able
8,021
8,021
Totsl incom
(364.71171
(Il5}
Expenthlu
Direct w(ryert and (klfvwi v)5ts
1375.(
4343fj6
31.6
Supw>rtaKI th1Thstratbve r05ts 2.164185
2.W,142
180.thts)
13.8
Total ey4)eralitsJTe
Vwiante perrentsr$4reethwe5%ed rEtsti¥elo bu¢*et forrred fj in •OMce.
Income
Total income for the period was £3.094.584, compnsing lunding income of £3.086.563 and interest receNable
of £8,021. Funding income was £372,728, or 10.8%. below the budget of £3,459.291. The principal reasons for
the variance were".
timing of milestone recc¥Jnrth
a delayed contract stsrt
Interest receNable of £8.021 was eamed on cash balances hekl on deposit during the period and was not
separalety budgeted.
Expenditure
Totsl expenditure for the period was £3.104,880 against a budget of £3.459.202. an underspend of £354,323
110.2°h}.
Direct projecl and delivery costs
Direct costs of £940.694 were below budget This underspend is closely linked to the lower reported total in
fijnding income, refleth'ng the variable nature of project delivery costs. which are incurred as funded aetivily is
Lbndertaken.
Support and adminisbative costs
Support and administr*ive costs of £2.164.185 exceeded budget by 3.8%.
E¥ceplional wsls
Exceptional eosls of £11.907 were Ir￿rred during the perK)d. They are one off. non-recurring. and not linked to
in year operations.
Result for the pefiod
The leadership team also monilor the underI￿n9 operating result, which excludes exceptional and nonrycash
items. as an indicator of the sustainability of ongoing 0per*"Crf￿.
Page 5

DocusKJn En%*t0pe ID.. 80c8ED2F.F7B34￿7.E9811C6OO*2
TREAT-NMD Alliance Ltd
Trustees, report (continued)
Period ended 31 December 2025
Table 2- Remft(iliatton of the statutory rewft to thE Undert￿ry operating result
Amount 1£)
Ilet forthe per*Jd
(10.296)
Add back". exceptlonal costs
IL907
Add back.. dePre0a￿On cha￿￿
3,201
unde￿ing operatfn8 reA
4.812
Budgeted result
Favoufable Varian￿ a8atnst I￿￿get
4.723
The undthwngoFeratir¢Ie5￿t bnota Th￿￿￿d￿hr￿￿I￿rtheth3ntie5 SORP 15 wesented a5 wlplernent￿Inf￿rrnatsD
Analysis by constituent period
The table below analyses the resuh of the exlended accounting period between the fve nx)nths lo 31 December
2024 and the tsvefve months lo 31 Detember 2025. The deficrt arose entirely in the earlier fwewmcmth period,. the
Group relurned a surplus in the Ca￿ndar year 2025.
Table 3- Result analysed betweeTrlhe fl¥e monthslo 31 Decefft￿ 2024 and the yearto
31 Dècember 2025
Aus- Dec
2024
IS monthsl
Jan- Dec 2025
112 month5)
TotAI
117 monlhsl
Fundlng Income
637.032
2.449.531
31￿&.56￿
InteFe51 ￿(￿l¥able
1797
5.224
Total income
1454.755
3m4.584
Dlrert projert and deli¥ery costs
(396.0931
1544.6021
1940.695)
support and adminislratrwe cos15
{fa7A30)
11,526,355)
12.164.185)
Total expendilure
IL0333231
(2J170.9571
P4et (der￿lt
/ income
1394.0941
The f￿￿K*￿th period to 31 Decernkn 2024carried a di5￿c￿￿ale Sh￿ of 5￿port athnir*sbalr*e costs
relatibrtolthe fundir¥ ihrvrne rEfWi5ed iftll*xerfthiths. reAeLtsEthe s￿sOnal profile.
Page 6

Docu5i9rn Enveltspe ID." B￿8EO2F-FI8mSrA-eO37￿81lc6fiO562
TREAT-NMD Alliance Ltd
Trustees, report (continued
Period ended 31 December 2025
Golng concern
After making appropriate enquiries, the trustees have a reasonable expectation that the company has adequate
resources to continue in operabonal existen￿ for the foreseeab￿ future. For this reason, they continue to
adopt the going concern basis in preparing the ffinancial stslements. Further details regarding the adoption of
the going concem basis can be found in the accounting poli¢4e$_
Resenf&s policy
Th8 reserves policy for TREAT-NMO Ltd ¢￿tInUeS to build reserves to support the charily's objectives
and to ensure the group's t)bjeclives can be delwered rf the￿ were any short term reductions in extemal
funding, lo support investments and actmties in the Netsvork. This involves ensurirsg that al least 6 months
salary cosls are available al each year end period (excluding the grant covered fixed temi personnel), which
totals £440,000. Al the end of the period. free reserves amounted to £808.623 which is above the largeled level.
Teflecling the investment in the PaLaDln project expected over the coming years. The Iruslees are satisfied with
the year end position.
Structure. govefnance and management
Constitution
TREAT-NMD Alliance Ltd is registered as a charitable wnpany limited by guarantee with company number
12099857 and registered Charity number 1200765. 11 is goveme(J by Art￿leS of Association adopted by 5peeial
resolution dated 7 November 2023.
Methods of appointment or e￿CtIOn of trustees
No formal policy is in place for the appointrnenl or election of trustees. Trustees are recruited and appointed
based upon the kntrwledge, skills and experien￿ judged lo be necessary and appropriate for the group.
Trustees are recruited from within the Global Ne￿ork for disease spe¢thc kr￿wledge and from wider circles for
relevant business knowledge. Newcastle UnNersty is entitled lo appoint one trustee to TREAT-NMD Alliance
Ltd. New apwnlments are appToved at Board level.
Organlsational slructurg and docisionwmaking policies
The managernenl of the chartty is the responsibility of the tnjstees who are elected under the terms of the
conslitLrtion, but the effective day lo day management is delegated to the Chief Execytive and staff wilhin the
group.
Policies adopted for the Induction and training of trustees
No formal policies a￿ in place for the inductNJn and training of trustees. New trustees are provided with key
documents and policies, including terms of reference and expectab"ons. Trustees are ab￿ to have indudion
meelings wrth key staff. including the Chief Executive. rf required.
Risk manag8rnent
The trustees have high ￿Ve1 oversight of risks wrth the higher risk items on the Risk Register revwed quarterly
al the Boald meetings of both charity and trading companies. The detailed risk management in operations and
finance is managed on a day-ltrday basis by the Chief Execuknve and senior staff in the group.
Page 7

Doeusv4Th El￿￿)￿* ID" Boc8E02F￿7B￿e￿A-OO37￿g811c6sD562
TREAT-NMD Alliance Ltd
Trustees, report (continued)
Period ended 31 December 2025
Disclosure of information to auditors
Each of the persons who are trustees al the time when this trustees, report is approved has confirmed that:
so far as that trustee is aware. there is no re￿an1 audrt information of whieh the charitable group's
audrtor5 are unaware, and
that IrLbslee has taken all the steps that ought lo have been taken as a trustee in order to be aware of any
relevanl audit information and to establish that the chari(able group's auditors are aware of that
inf0mat￿.
Auditors
The auditors, UNW LLP, have indicated their willingness lo continue in offf￿. The designated trustees will
propose a motion reappointing the auditors at a meeting of Ihe Iruslees.
Approved by order of the members of the board of Iritstees on 24 September 2026 and signed on their behalf
by..
Prof Volker Wilhelm Straub
Director
Page 8

Do¢uswJn Efi￿Fe ID." BCC8ED2F.F78MKA4037E9811C68D562
TREAT-NMD Alliance Ltd
Statement of trustees, responsibilities
Period ended 31 December 2025
The trustees (who are also the director5 of the charty for the purposes of company Lwl are responsible for
preparing the truslees. report and the financial ststements in accordance with applicable law and United
Kingdom Accounting Standard5 (Unrted Kingdom Generally Aceepled Accounting Practicel.
Company law ￿qUI￿$ the trustees lo prepare financial ststements for each financial year. Under company law,
the trustees musl not approve Ihe financial ststements unless they are satisfied that they give a true and fair
view of the slate of affairs of the group and the charrty and of their incoming resource5 and application of
resources. including their income and expendrture. for thal penod. In preparing these financial statemenls, the
trustees are required lo".
select suilsble accounting policies and then appty them consistentty."
observe the methods and principle5 of the charib.es SORP {FRS 1021"
make judgments and accounting eslimales that are reasonable and prudent."
stale whether appluble UK Accounb"ng Standards IFRS 1021 have been folknved, subject lo any
material departures disclosed and explained in the finanual statements.
Pfepare the financial statements on the going concem basis unless it is inappropriate to presume Ihal the
group will continue in business.
The trustees are responsible for keeping adequate accounting records that are sufficient 10 show and explain
the group and the Charitys transactions and dI￿10$e wifh reasonable accuracy at any time the financial position
of the group and the charity and enable them lo ensure that the financial statements comply with the Companies
Act 2006. They are also responsib￿ for safeguarding the assets of the group and the charity and hence for
taking reasonable steps for the prèvention and detection of fraud and other irregularities.
Approved by order of the members of Ihe boafd of trustees on 24 September 2026 and signed on ils behalf by..
Prof Volker Wilholm Strnub
Trustee
Page 9

DoDJsvJn Envdope10.. BoC8ÉD2F.F7BM9CM037￿96l IC68D562
Independent auditors. report to the members of TREAT-NMD Alliance Ltd
Opinion
We have audi(ed the financkal statements of TREAT￿MD Alliance Ltd Ilhe parent Charrtab￿ companYI and its
subsidiaries ('Ihe group'l for the period ended 31 December 2025 which ￿MpriSe the consolidated slalemenl of
financial aclivitses, the consolidated balance sheet. the charity balance sheet. the w)solidaled slalemenl of
cash fl¢)ws and the related notes. including a summary of sKjnrf￿anI accounting policies. The financial feporting
framewoth that has been applied in their preparation is appluble law and Unrted Kingdom Accounting
Standards, including Financial Reporting Stsndard 102 The Financial Reporting Standard applicable in the UK
and Republ￿ of Ireland. (Unrted Kingdom Generalty Accepted Accounting praCt￿e).
In our opinion the financial slalements-
give a Irue and fair view of the stsle of the group's and of the parent charitable companls affairs as al 31
December 2025 and of the grovp's inctyning resources and application of resources, including its income
and expenditure for the period then ended..
have been properly prepared in accordance with United KIngd￿n GeneraNy Accepted Accounting
Practice,. and
have been prepared in accordance with the requifements of the Companies Act 2006 and the Charities
Ac12011.
Basis for opinion
We conducte(l our audit in accordance IntematKtrnal Standards on Audiling {UK} I'ISAS IUKI'I and
applieable law. Our responsibilil*s under those stsndards are further described in the 'Audrtots' responsibilrties
lor the audit of the financial slaternents. section of our report. We are independent of the group in accordance
with the elhical requirements that are rdevanl to our audii of the ffinanckal statements in the Uniied Kin9dom,
including the Financral Reporting Covncifs Ethical Standard, and we have fulfilled our other ethical
responsibilities in accordan￿ wrth these requirements. We believe that the audrt evidence we have obtained is
suff￿￿nI and appropriate lo provide a basis for opinion.
Conclusions relating to going concem
In au¢Jiling Ihe financial ststements, we have concluded that the twslees. Ltse of the going concern basis of
aceounting in the preparation of the financial slatemenls is appropriate.
Based on the work we have performed. we have not Alentsf￿ any material uncertainties relating lo events or
condition5 that, indNidually or collectivety, may cast doubt on the group's or the parent charitable
company's ability lo continue as a going coneem for a pernd of al least twelve months from when the financial
slalements ale aulhorTsed for issue.
Our responsibrfilie$ and the responsibilrt￿s of the trustees wilh respect to g￿n9 concern are described in the
relevant sections of this report.
Page 10

Oo¢usvJn En¥elope ID.. ￿aE02F.F78$8￿8o37￿98I1c68lj562
Independent audltors. report to the members of TREAT￿MD Alliance Ltd (continued)
Other Infom)atlon
The other information comprises the information included in the annual report other than the financial
stslements and our auditors. report the￿on. The trustees are responsible for the other information contained
wthin the annual report. Our opini¢)n on the financial stslements (%)es not cover the other information and,
except to the extent otherwise expl￿1t￿ slated in our report. we do not express any form of assurance
conclusion thereon. Our responsibilily is to read the other information and. in doing $0, consider whether the
other infomiation is malerialty inconsistent wrth the financial ststemenls or Ouf knowkdge cbtained in the eourse
of the audit, or othe￿ise appears to be materially misstated. If we hdentify such material inconsistencies 01
apparent material misslalemenls, we are requiied to determine whether this gives rise lo a material
misstatement in Ihe financial statements Ihemselves. If, based on the work we have performed. we conclude
Ihal there is a material misstaterr£nl of this other InfO￿atiOn. vft ae required to report that fact.
We have nOth￿g to report in this regard.
Opinion on other mattels prescrlbed by the Companies Act 2006
In our OFHnw. based on the work undertaken in the Course of the audit..
the information given in the Trustees. report for the fina￿la1 year for which the finaneial slalemenls are
prepared is consistent wrth the financial statements.
the Truslees. report has been prepared in aCcorda￿e wrth applicable legal requirements.
Matter5 on which we are required to feport by exc•ption
In the light of our knowledge and understan(Jing of the charitable company and its environment obtained in the
course of the audit, have not ldentrf￿d Materi￿ misstatements In the Trustees, report.
We have nothing lo report in respect of the folkM"ng Matte￿ in relation to which Companie5 Act 2006 requires
us lo report lo you if. in our Opin￿n..
the parent chantable company has not kept adequate and sufficient accounting rewrds. or returns
adequate for our audit have nol been recewed from branches not visited by us". or
the parent charitable company financ￿1 statements are in agreement with the accounting reccfd5 and
returns., or
Certain di￿10$ureS ol Iruslees. remuneration spe¢thed by law are not made,. c
we have not received all the information and explanations we require for our audit," or
the Iruslees were not entitled to prepa￿ the financkAI stslemenls in accordance with the small companies
regime and lake advantage of the small Companies, exemption5 in preparing the Tnjstees. report and
frcln the requirement lo p￿p￿e a Strategie report.
Page11

Docu5vJn En¥eloF¢ ID.. Btc8E02F.F7B>89C￿￿37￿96l IC68D562
Independent auditors. report to the rnembers of TREAT-NMD Alliance Ltd Icontinued)
Respon5ibilitie5 of trustees
As explained more fulFy in the truslees. responsibilrties stalenEnt. the trustees (who are also the direetors of the
charitable company for the purposes of company Iwl are responsible for the preparation of the financial
slalemenls and for being Satisf￿ that they gtve a true and fair view, and for such internal control as the
trustees deteimine is necessary to enable the preparalK*n of financial statements that are free fr¢)m material
misslalement. whether due lo fraud or effor.
In preparing the financia statements. the trustees are responsible for assessing the group's and the parent
charitsble companvs abilrty to eontinue as a going concern, disclosing. as appl￿ble. malleT5 Telaled lo going
concern and using Ihe going concern basis of accounting unless the tnjslees erther intend to liquidate the group
or Ihe parent charitable company or lo cease opeTrtKJn5. or have no realistic altemalive bul lo do so.
Auditor5. responsibilities for the audit of the financlal ststements
Our objectives a￿ to obtain reasonable assurance aboul whether the financial statements as a whole are free
from malefial misstatement. whether due to fraud or error. and to issue an auditors, report that includes our
opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audrt Conducted in
accordance with ISA5 IUKI will a￿ayS deled a material misslalement when (( exisls. Misslatemenls can arise
from fraud or error and a￿ considered material rf. indivhlualty or in the aggreg*e, they could reasonably be
expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibTrlrties for the audrt of the financial sL*emenls is kaled on the Financial
Reporting Ccmjncil's website at". Vfv•W.frc.org.ukJaudrt0￿lesponSIbl1th.e5. This description forms part of our
audilorfs report_
Extent to which the audit was considered capable of detecting irregularities. including fvaud
Irregularities. induding fraud. a￿ instances of non-￿Mpli0nce with laws and regulations. We design
pr¢xedures in line wrth our responsibiltti"e5. Outlined above, to detect material misslatemenls in respect of
Irregularities. including fraud. The extent to which tsjr PTiJcedures are Capable of deteding irregularities,
including fraud is delailetl be￿￿. H￿ever, it is the primary responsibilty of mana9emenl, with the oversight of
Ih05e charged wrth g¢)vernance. lo ensure that the enttys operations are conducted in accordance with the
provis￿nS of laws and reguL￿"OnS and for the prevents.on and deteckn.on of fraud.
We obtain and update our understanding of the Charitab￿ c(xnpany. rts activities. rts control environment, and
likely future developments. including in relation lo the legal and regulatory framework applicable and how the
charitable company is cOmpl￿ng with that framthvork_ Based on this understanding, we identify and assess the
risks of material misstatement of the finan￿al slalements. whether due lo fraud or error, design and perform
audf( procedures responsive lo those risks. and rt¢lain audrt evKlerKe that is sufficient and appfopriale to
provide a basis for our opinM. Thi5 includes considerats.on of the risk of acts by the entrty that were contrary lo
applicable laws and regulations. inclLKling fraud.
Based on our understanding of the charitable company, we identif￿d that the principal risks of non-compliance
with laws and wulalions relaled lo laws and regU￿tIonS thal directly affect the financial statements including
financol reporting legislation (including related companies legislalionl. distributab￿ profils legislation, pension
legislation and UK tsx kgislalion. Irb addrt￿n. the ¢haritable company Is subject lo many other laws and
regulations where the consequences of non<ompliance could have a material effecl on amounts or disclosure5
in the financial statements, foi inslartce through the imposrtion of fines and Irtigat￿n. We considered the extent
lo which non-compliance wrth Ws and regulations mvJht have a material effect on the financial statements and
we have as$e5sed the extent of compliance tmth these and regulations a5 part of our procedures on the
related financial ststemenl ￿ern$.
Page 12

Docuslw En¥elow10: BOc8ED2F_F7Bu9CA-￿37.Eg3I1CG8D562
Independent auditors. report to the members of TREAT-NMD Alllance Ltd (continued)
We also evaluated management's incentives and opportun￿"eS for fraudulent manipulation of the financial
slalemenls linduding the risk of ovemde of conlrds} and detemiined that the principal risks related lo posting
inappropriate journal entr￿$ to manipulate financial resutts. management bias in accounting eslimales, as well
as improper income recogn((ion whKh includes fraudulent posting of journal entries lo int￿ne.
Audit procedures performed by the engagement team included".
. Inquiry of management and those charged 7Mth govemanee regarding xtual and potential hligation or claims
as wèll as whether they have knowledge of any actual. suspected or alleged fraud,"
Reviewng the financial stalement disclosures and tesling to supporting documentation lo assess c￿nplIance
th applicable laws and regulations".
Rewewing m*ing minutes to Klenlfy rep￿ted frauds arKI any potential non-compliance wrth laws and
regulalion$,'
Identifying journal entries based on risk criteria and lesling Ihe ldentrf￿ entries to suppth'ng documentation,
in particular joumal entries wrth unusual account combinalDns', and
Challenging assumptions and judgments made by management in their swnificanl accounting estimates and
evaluating whether there was any evidence of bias by the trustees that r8presenled a risk of material
misslatemenl due lo fraud.
Because of the inhefent limitalk)ns of an au¢Jit. there 1$ a risk that we will not delecl all irregularities. including
those leading to a material misststement in the financial stalements or non-compliance with regul*ion. This risk
increases the more that compliance wth a law or regulat￿n is removed from the events and transactions
reflected in the financial slatemenls. as we wll be less likely lo beca￿￿ aware of instances of non-wmpliance.
The risk is also greater regarding Ir￿Ul8n11es occurring due to fraud rather than error, a$ fraud involves
intentional concealment. forgery. co#usion. omission or misrepresen1at￿n.
Use of our report
This report is made solely lo the charivs trustees. as a brxly, in accordance wth Chapter 3 of Part 16 of the
Compan*s Act 2006. and lo the charrtable companls Iruslees. as a body, Part 4 of the Charities (Accounts and
Reports) Regulations 2008. Our audrt Wofk has been undertaken so that we might slate lo the charity's trustees
those matters we are required to State lo them in an audrtors. report and for no other purpose. To the fullest
extent permitted by law, we do not accept or assume responsibilty lo anyone other than the charitable company
and its members, as a body. for our audi( work. for this report. or for the opinions VR have fomed.
A_ LI￿al
s￿orK461F4SE_
Anne Hallowell Bsc DChA FCA (Senior Statutory Auditor)
for and on behalf of UNW LLP. Statutory Auditor
Chartered Accountants
Newcastle upon Tyne
24 September 2026
Page 13

DouJsi9n Envdope ID.. B0C8ED2F-F7B>8￿￿1037-E9&11c68D5S2
TREAT-NMD Alliance Ltd
Consolidated Statement of financbal actlvities (incorporating income and expenditure
account)
Period ended 31 December 2025
Unrestricted
Restricted
Total
Total
funds
funds
funds
funds
17 months to 17 months to 17 months to
12 months lo
311)ecember 31 December 31 December
31 July 2024
2025
2025
2025 {as reslaled
Note
Income from:
Grants and donations
ChaTilable aetivilies
Other trading activities
Interest receNable
458.177
458.177
943,565
1,684,821
8.021
114.807
478.182
1,884.343
1,719
943.565
1,684.821
8.021
Total Income
2,636.407
458.177
3.094.584
2.479,051
Expenditure on..
Raising funds
Charitable activitie5
2.330.217
316.486
2.330.217
774,663
2.1 $0,531
367,884
458.177
Total expenditure
2.646.703
458.177
3,104,880
2.518,415
Net movement in funds
{10,296
(10,2961
139,364}
Reconclllatlon of funds:
Total funds brought forward
Net movement in funds
837.146
{10.296)
837,146
110,296)
876,510
139,3641
Total funds ¢anied fonvard
826.850
826.850
837.146
The notes on pages 18 10 35 fomi part of these finan￿al statements.
Page 14

DocuthJTh En¥elcoe ID". B￿8FD2F.F7B>&9CA4037￿g81 IC68D562
TREAT-NMD Alliance Ltd
Consolidated balance sheet
At 31 December 2025
31
December
2025
31 July
2024
Notg
Fixed assets
Tangible a5set5
13
18.227
6,596
18.227
6,596
Current assets
Debtors
Cash at bank and in hand
15
796,426
1.644.122
884,476
1,116,176
2.440,$48
2,000,652
Creditors.. amount5 falling due wthin one
16
{665.790)
(1.020.772)
Net current assèts
1.774.758
979,880
Creditors.. amounts falling due after more
than one year
17
{966.1351
1149.330}
Tolal net assets
826.850
837,146
Charity funds
Restricted funds
18
unrestr￿ted funds
18
826.850
837,146
Total funds
826,850
837,146
The Iruslees acknowledge their responsibiif(ies for eomplyiry 7*Mh the fequiremenls of the Act %wth respect lo
accounting records and preparation of financ￿1 ststements.
The financial statements have been prepared in accordance wrth the p￿slOn8 apph'cable to entitie$ Subject to
the small companies regime.
The financial statements ￿tre approved and aulhofised for issue by the trustees on 24 Seplember 2026 and
signed on their behalf by.
VdLLY SlrALIl•
Prof Volker Wllhelm Straub
Trustee
The notes on pages 18 to 35 fom) part of these financial statements.
Page 15

Dotsjsign ErweloFe ID.. 8oceEO2F.F78>8￿￿037.E98lI¢680562
TREAT-NMD Alliance Ltd
Balance sheet
At 31 December 2025
31
Decembèr
2025
31 Juty
2024
Note
Fixod assets
Investments
14
Current assets
Debtors
Cash al bank and in hand
15
30.250
71.513
38,834
499,811
101.763
538,645
CTedrtors.' amounts falling due wthin one
year
16
{92.125)
1529,007)
Net currnnt assets
9.638
9.638
Total assets less Current liabilities
9.643
Total net assets
9,643
Charlty funds
Restficled funds
Unrestricted funds
18
18
9,643
Total funds
9.643
9,643
The companls nel movement in funds forthe perKxI was £nil (2024.. £141.568)1.
The Iru$tees acknowledge their responsibiltties for complying ￿th the requirements of the Act with respect lo
accounttng records and preparation of financial statements.
The financial slalements have been prepared in accordance with the provisKJns applicable to enlth.es subject to
the small companEs regime.
The finanual slalements were appfoved and authorised for I￿Ue by the tTuslees on 24 September 2026 arbd
s￿ned on their behalf by..
V6LLLY
Prof Volker Wilhelrn Straub
Trustee
The notes on pages 18 to 35 fom part of these financial ststements.
Page 16

DoDJsi9n Ertvdope ID.. 80C6ED2F-F7B34¥fA4037￿98lle6oDS63
TREAT-NMD Alliance Ltd
Consolidated statement of cash flows
Period ended 31 December 2025
17 months
to31
Decembor 12 months lo
2025 31 July 2024
Note
Cash flows from op•rating activities
Net cash from operatsng activit￿$
20
542.778
395.306
Cash flows used In Investing activities
Purchase oftsngible fixed assets
(14,8321
14.794}
Net tash used In Investlng actlvltfjes
(14,8321
14.794)
Cash flows from financing activities
Net cash provided by flnancing activities
Change in cash and cash equivalents in the year
Cash and cash equNalents at the beginniThJ of the year
$27.946
390.S12
1.116.176
725,664
Cash and cash equivalents at the end of the year
21
1,644.122
1.116,176
The notes on pages 18 10 35 fonn part of these financial ststements
Page 17

Dovjsign Enve￿)￿ ID." B(uED2F.F7Bu9C￿7.E9811Cfj8D
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Ggneral Inforniation
The company 1$ a company Iwnbted by guarantee. The members of the company are the trustees named
on page 1. In the event of the company being wcyjnd up. the Ikgbility in respect of the guarantee is limited
10 £1 per member of the company.
Accounting policies
2.1 Basb of preparntlon of financial statoments
The financial statements have been prepared in &cordanee with the Charities SORP IFRS 1021
Accounting and Reporting by Charities.. Statement ol Recommended Practice applicable to charities
prepanng their accounts In accordance wrth the Financol Reporting Standard applicab￿ in the UK and
Republic of Ireland IFRS 102) (effective 1 January 2019), the Financial Reportiw Standard applicable in
the UK and Reputs1￿ of Ireland IFRS 1021 and the Companies Act 21yffj.
TREAT-NMD Alliance Ltd meets the definrtion of a public benefrt entrty under FRS 102. Assets and
liabilities are inilialty recognised al hsslorical cost or Iransadion value unless otherwise slated in the
relevant accounting policy.
The current reporting period of 17 months frt>Tr 1 August 2024 10 31 oe￿mber 2025 is longer compared
to the prior year reporting peiitrJ of 12 months from 1 August 2023 10 31 July 2024. This is due to the
trustees, decision lo extend the reporting period. As such. the comparalwe amount5 presented in the
financial statements are not diredy comparabk_
The financial Ststemenls are presented in pounds sterling and rounded lo the nearest pound.
2.2 Basis of Con￿￿ldat10n
The consolidated slalemenl of financial activities ISOFAI and consolidated balance sheet consolidate the
financial slalemenls of the group and rts subsKliary undertaking. The results of the subsidiary are
consolidale(l on a line by line basrs.
The group has taken advantage of the exemptKJn allowed under section 408 of the Companies Ad 20(6
and has not presented its own stslement of finanaal athl1￿ in these financial statements. A summary
of the charitys result for the period is shcmin in note 11.
2.3 Golng concem
The group meets its working capital requirements through its cash balances and operating cash flow5.
The trustees have prepared financial forecasts Wh￿h, hawng regard for reasonably possible changes in
trading performance as a result of current economic environment. indicate that the charitable group will
maintain sufficient financial headroom to enable rt to ccinlinue meeting rts liabilities as they fall due in the
normal eourse of business for at least the next months following approval of these financial
5talemenls. At the balance sheet dale, the group held deferred income representing grant funding
received in advance of project delivery and assoualed expendrture commilmenls. Forecasts prepared by
management demonstrate that the funding currentty secured. toyether with cash reserves and anticipated
fvlure grant receipts, will be sufficient lo meet the group's operab.onal and pioject-reiated obligations as
they fall due.
The trustees have revmved a range of scenari05. including variations in the timing of project expendilure
and grant income re￿nitIOn. and are satisfied that adequ*e financial resources are available for the
foreseeable luture. Aeeordingty, the trustees continue lo adopt the 90ing concem basis in p￿ paring the
financial slalements.
Page 18

Dowsign Envdope ID.. 8oC8ED2F-F7B3-89G44037￿98lICB8Dyo2
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Accounting policies Icontlnued)
2.4 Income
All income is recognised once the company has enlrtlemenl lo the income, rt rs probable that the income
will be received and the amounl of in¢￿￿e receNable can be measured reliabty.
Grants are induded in the consolidated slalemenl of financial activities on a receivable basis. The
balance of income received for specrfic purposes but not expended during the period is shown in the
relevant funds on the balance sheet. Where income is recewed in advance of entitlement of receipt, ils
re¢¢gnition is deferred and Induded in credrtors as deferred ineome. Where entitlement occurs before
income is received, the income is accrued.
Other income is recognised in the peri¢￿￿ in Wh￿ rt is receivable and to the extent the goods have been
provKled or on completion of the servti.
Trading income comprises revenue rewnised in respect of ser¥Kes supplied during the year, of
discounts and excluding Value Added Tax.
Trading income is fewgnised as services are provided. Where a contrad ha5 only been partially
completed al the balance sheet date, tumovef represents the fair value of the service pTovidecl to date
based on the stage of C¢Jmpletion of the contract activity al the balance sheet date. Where payments are
feceived from customers in advance of services provided. the amounts are recorded as deferred income
and include{* as part of credilors due wrthin one year.
2.5 Expenditure
Expenditure 15 recognised once there is a legal or constwctNe obligation lo transfer economic benefit to a
third paty. rt is probable that a transfer of economic beneffts wll be required in settlement and the
amount of the obligation can be measured reliably. Expenditure is classified by aclivty. The costs of each
activily are fflade up of the lolal of dTrrect costs and Sha￿ costs. including support costs invofved in
undertaking each actNty. Direct costs attributable lo a single activty are allocated directly lo that aclivily.
Shared costs which contribute to more than one actrvty and sUPPOrt cost5 wh￿h are not allributable to a
single aclivty are apportioned between those activrties on a basis consistent with the use of resources.
Central staff ¢osls are all0￿?ted on the basi5 of time spent, and deprecialK)n charges allocated on the
portion of the asset's use.
Expenditure on chantable adiviltes is incurred on direclty undertaing the xtivilies which further Ihft
group's objedives, as well as any associated support costs_
2.6 Employee benefits
Short-tem? benefits
Short4em beneffts, indudiTh3 hdiday pay and other similar non-monetary benefits, are recognised as an
expense in the per￿ in I￿1¢h the servv is received.
Defined contn.bulvl￿ pension plan
The charitable company operates a defined contribution pensK*n pLan for rts employees. Contributions are
recognised as an expense when they fall due. kniounls due but not yel paid ale included within creditors
on the balance sheet. The assets of the plan are held separalety from the company in independent
administered funds.
Page 19

Do¢w$ign En%tknF* ID. BQC8Eo2F478>8￿8037￿98l IC680562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Accounting pollcies {eontinued)
2.7 Foreign Currency
rransactions and balances
Transxlions in foreign currencies a￿ translated into sterling using the spot exchange rates al the dale$
of the Ifansaclions. At each period end. foreign currency monetary assets and liabilities are translated
using the closing late. Foreign exchange gains afKJ l¢)sses are reco3nised in the statement of financial
acliviljes.
2.8 Tangible fixed assets and depreciation
Tangible fixed assets are sL*ed al cost. less accumulated depreekation and accumulated impairment
losses. Cost indudes the original purchase price plus any further costs di￿¢ttY altribulable lo bringing
the asset to its working Cond￿on for its interKl&J use.
Depreciation is provided on all tangible fixed assets at rates cakulated to write off the cost of fixed
assets, less their estimated resKlual value. over their estim*ed usefvl lives as follows..
Fixtures ar￿ frttings
Computer equipment
25% straight line
25% slraight line
Asset residual values and useful lives are rewe4ved al the end of eath reportin9 period. and adjusted
if appropriate. The effect of any change is accounted for prospeclNely.
2.9 Inv•stments
Fixed asset investments are a fomi of financial instrurnenl and are Initial￿ recognised at their transaction
cost and subsequentty measured al fair value at the balan￿ sheet date. unless the value cannot be
measured reliabty in which case it is measured al cost less impairment. Investment gains and losses,
whether realised or unrealised, are combined and presented as 'GainsllLossesl on investments, in the
consolKl*ed stslement of financi￿ actlvrt￿.
Investments in subsidiaries are valued at cost less provis¥)n for impaimient.
2.10 Debtors
Trade and other debtors are reccgnised at the settlemerrt amount after any IrwJe discount offered.
Prepayments are valued al the amunt prepaid net of any trade discounts dLte.
2.11 Cash at b•nk and In hand
Cash at bank and in hand indudes cash and short-temi highty liquid investsnents with a short maturity of
three months or less from the dale of xquisiti.on or opening of the deposrt or simikr account.
Pa9e 20

DOc￿l9n.En¥4Ope ID". BoceE02F.Ff8>89CM037-E9811C680%2
TREAT-NMD Alliance Ltd
Notes to the financial ststements
Period ended 31 December 2025
Accountlng pollcles (continued)
2.12 Liabilities and provisions
Liabilrties are recognised when there is an obligats.on at the balance sheet date as a result ol a past event,
is probable that a transfer of econorruc benefit wll be required in settlement, and the amount of the
settlement can be estimated reliabty-
Liabilities are remgnised * the amount that the cornpany anti¢ipales it will pay to Sett￿ the debt or the
amount it has received as advanced payments for the goods or services il musl provKIe.
Provistrjns are measurejj at the best estimate of the amounts required to settle the obligation. Where the
effect of the time value of money is material. the provision is based on the present value of those
amounts, discounted at the pre4ax discount rate that refiects the risks specific to the liabilty. The
urwinding of the discount ts rewnised in the consolidated statement of financial 8Ctwities as a finance
cost.
2.13 Financial instruments
The charrtable gTOUP onty enter5 into basic financial instruments Iransactions that ￿sum in the recognition
of financial assets and Irabilrties like trade and other accounts receivable and payable and cash and bank
balances.
Al such instruments are initralfy recognised at transaCt￿n price. unless the arrangement conslrtutes
financing transaction, in which case the tranSa￿￿n is measured al the present value of the future
receipts discounted al a market rate of interest. AU ffinancial instrbjnents are subsequently carried al
amortised mst usin9 the effective interest rnelhc*J.
Z14 Fund accounting
General funds are unrestricted lunds which are available for use at the discretion of the Iruslees in
furtherance of the general oty'ectives of the group and wh￿h have nol been designated foi other
purposes.
Restricted funds are funds which we to be used in accordance wth specifTrc restricltons imposed by
donors or which have been Taised by the group for part￿lar PUTposes. The costs of raising and
administering such fvnds are charged against the specifc fund. The aim and use of each restri¢led fund
is $91 out in the rbotes to the financk31 statements.
Investment income. gains and bsses are alk)cated to the appropriate fund.
Critical accounting estimates and areas of judgrnent
Estimates and judgments are continualty evaluated and are based on historical experience and other
factors. induding expectations of future events th* are believed to be reasonable under the
Circumstances.
In preparing these financial statements the tnjstees do not consider there were any si9nrfi¢anl areas of
judgment or aceounling eslimales, other than those noted below that were required m apptying the
group's accounlmg policies as set out atw)ve.
Deferred income
A significant judgement has been made in determining the amourrt of grant funding that should be
deferred at the reporting date. Funding received for the PaLaDln project is subject lo reStr￿IK)nS and
future perfomiance obligatkjns and. accordingly. amounts reLats"ng to future project activitie5 have been
recognised as deferred income until the a550ciated costs are incurred and rekvanl condition5 are met.
Page 21

Docu$KJn Envel)k*10". 8tCeED2F￿7B>a9C￿Wj7.E98I1C68OSfj2
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Income from grants and donalions
Restrictèd
Total
funds
funds
17 months
17 months
to31
to31
December December
2025
2025
PaLaDln proieet grant
458,177
458.177
Re5trided
funds
12 months
to 31 July
2024 las
restated)
Total
fund5
12 months
10 31 July
2024 las
reslatedl
PaLaDln project grant
114,807
114,807
The comparalNe ffigures in these finanual statements have been reslaled lo reclassify the group's
income and associated expendriure relating to funding received by the group's subsidiary undertaking in
the prior year in respect of a PaLaDln project grant_ Income from grants and donations together with
expenditure on chafitable aclmties have been increased by £114,807. wrth corresponding reductions in
income from other trading aclivrties and expendiluie on raising funds. respedively. The Iruslees cgnstder
that Ihis reslalement. together wrth classification of the grant weipls and related expenditure within
restricted rather than unrestricted funds, more appropriately refflect5 the nature and terms of the project to
which these transactions relate. This restatement does not have any effect on the group's movement in
reslricled or unrestricted funds nor on the group's tolal funds, as previously reported.
Income from charitable activities
Unrestricted
Total
funds
funds
17 months 17 months
to31
to31
December De¢emb•r
2025
2025
Educalional activrties income
943.565
943,565
Page 22

Docuslw Enw8l¢pe ID.. WK8Eo2F.F78￿Th8O37.E9Bl1¢68D562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Income from chaiitable activities (continu￿)
Unreslricled
funds
12 months
to 31 July
2024
Totsl
funds
12 months
10 31 July
2024
Educaltr?nal activities inccffie
478.182
478,182
Income from other trading activities
Income from non charltable Irading activities
Unrestricted
funds
17 month5
to31
December
2025
Total
funds
17 months
to31
December
2025
Project income
1.684,821
1.684,821
Unrestricted
funds
12 months
to 31 July
2024 {as
restaledl
Total
funds
12 months
10 31 Juty
2024 las
reslaled)
Project income (see note 4)
1,884.343
1,884,343
Page 23

DooJ$iyn Envelope K).. BCC8E02F_F78>8KU037.E9811C68D562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Intsrest recelvable
Unrestricted
funds
17 month5
to31
December
2025
Totsl
funds
17 months
to31
December
2025
Interest receivable
8.021
8.021
un￿StriCted
funds
12 months
to31
Juty
2024
Totsl
funds
12 months
to31
July
2024
Interest receivable
1.719
1.719
Expenditure on raising funds
Stsbsidiary tiading expenses
Unrestricted
funds
17 months
to31
December
2025
Total
funds
17 months
to31
December
2025
Cost of sales
Exceptional administfalive expenses
Administration expenses
Tax credrt
Administrative staff eosls
168.291
11,907
622,551
134,050)
1,%1.518
168,291
11,907
622,551
(34.0501
1,561,518
2,330,217
2,330,217
Page 24

OrKuwgnEn¥dy ID.. 8OC8ED2F.F7834KA4037￿9B11¢fjeO£62
TREAT-NMD Alliance Ltd
Note5 to the financial statements
Period ended 31 December 2025
Expenditure on raising ￿Trds Icontinuedl
Unrestricted
fvnds
12 morblhs
10 31 July
2024 (as
restsled)
Total
funds
12 months
to 31 July
2024 {as
restsledl
Cost of sales (see note 41
Adminislr8l•Jn expenses
Tax credit
Administrative staff costs
733,994
426,892
(12.8981
1,002,S43
733,994
426,892
112,8981
1.002,$43
2,150,531
2.150,531
Analysis of expenditure by activities
Support
Total
DIr￿t costs
Costs
funds
17 Months
17 months 17 months
to31
to31
to31
December December
December
202S
2025
2025
Educational actiwty costs
PaLaDln pfoject costs
301.799
458,177
14,687
316.486
458.177
759.976
14,687
774,663
Adivknes
undertaken
directly
12 months
10 31 July
2024 las
reslaledl
Support
costs
12 month$
to 31 July
2024 las
resl*ed)
Total
funds
12 month$
10 31 July
2024 las
reslaledl
Edu¢ational actimty cost$
PaLaDln project costs (see note 41
239,215
114.807
13.862
253.077
114,807
354.022
13,862
367,884
Page 25

DO￿Srgn Énvelope ID.. 80C8ED2F-F78>89CMO37￿9e1lcoaD5S2
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Analysis of expenditure by activities {continuedl
Analysis of support costs
Total
funds
17 months
to31
December
2025
Total
funds
12 months
1031
Juty
2024
Office costs
Bank fees
Legal fees
Foreign exchange losses
11.387
1.360
504
1.436
7.493
871
4,303
1.195
14,687
13.862
10. Auditors. remuneration
2025
2024
Fees payable to the chantable ¢ompanY$ auditor for the audit of the
charrtable CoMpan￿S annual accounts
13.650
13.000
11. Charitable company results
The results of the charrtable company are sh¢ywn belcMT".
17 months
to 31 12 months
D￿ember
to 31 July
2025
2024
Income
Expenditure
Surpluslldeficit)
943.$65
478,182
) 7501
All funds were unrestrttted during the year.
Page 26

DocusignEn¥*fope ID.. 80C8ED2F.F7B>8StA4O37￿9&lIC68O562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
12. Staff costs
D•cernber2924
15 wiod)
D•c•rnlRr2025
qA2 month
periodl
2024
112 m•nth
perfodl
117 month
periodl
Wages and salarie5
&)clal securitycosts
Corrtributlonto defined
penslon scheme5
L340.526
15BJ
43252
115.048
92.718
15.ffi2
L116,019
1.561,518
L002.543
The chaTitable company ITREAT-NMD Alliance Ltd) has no staff costs or employees (2024.. nill.
The average number of persons empbyed by the charitatk group (wrthin TREAT-NMD Services Ltd)
during the periotlfyear was as fdl¢yws.'
Group
2025
No.
Group
2024
No.
19
19
The number of employees whose empbyee benefits (excluding empwr pension costs) exceeded
£60.000 was..
Group
17 months
to31
Decembei
2025
No.
Group
12 mnths
to31
July
2024
In the band £60,(K11 - £70.000
In the band £70,001- £80.000
In the band t90,001- £100.000
In the band £100,001 - £110,000
In the band £160,th)1 - £170.000
In the band £240.fy)1- £250.000
Page 27

DocusvJTh En¥eknpe10.. 8Lf8ED2F.F7B>8U8037.E9811C68D562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
12. Staff costs {¢ontlnuedl
The current reporting pell.od eovers 17 months 11 August 2024 to 31 December 20251. Comparatives
relate to a 12 month per#)J. Employee remuneration is disclosed based cffi lolal rernuneralion earned
within each respeclive period.
The key management personnel of the Charitable group comprise..
CEO
CEO
Headoloperations
HeadolCentralSer4tces
RealWoFidEwdefKe Manager
DataGts%*mar*e Mar*r
Head ol Educatlon & E*rrts
Busine555upportManagei
RealWoTld ENryde￿e Manager
Dats Manager
The total emth benefits of the key management personnel of the charitable group were as folk)ws'.
A*5ttoDeremb¢T J•nu•ryto Deremkn 2W25{17mgRth 20U{12morth
2tr24{Srno￿h pefivdl 2025112rnDAthwiodl
pwiodl
p¢riodl
Totsl
139.878
7.705
507,5&3
Page 28

DLKU51gn Envelope ID". 80C8ED2F.F7B>8W037.E9811C68D562
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
13. Tangible fix¢d assets
Group
Fixtures and
fittin95
Computer
equipment
Total
Cost
At 1 August 2024
Addfiions
17.397
12.763
19.261
14,832
2.069
At 31 December 2025
3,933
30.160
34,093
Depreciation
At 1 August 2024
Charge for the peTic*J
11.778
2.789
12,665
3,201
412
At 31 Decefflber 2025
1,299
14.567
15,866
Net book value
Al 31 Deeember 2025
2.634
15,S93
18.227
977
5,619
6,596
Al 31 Jufy 2024
Page 29

DocusvJn En¥*kJpe ID". BOc8E02F.F7B&89CU037￿8•Ic6005O2
TREAT-NMD Alliance Ltd
Notes lo the financial statements
Period ended 31 December 2025
14.
Fixed asset investments
Investrnents
in
subsidiary
companies
Cornpany
Cost
Al 1 August 2024
Al 31 Deeember 2025
Net book value
Al 31 December 2025
Al 31 Juty 2024
Principal subsidiari8s
The followin9 was a subsidiary undertaking of the charity.
Name
Company
number
Registered office or
principal place of
businwss
Class of
shares
Holding
Included in
consolidation
TREAT.NMD
Services Ltd
12110979
The Spark
Drayrnans Way
Newcastk Helix
Newcastle Upon Tyne
England
NE4 5DE
Ordinary
10N Yes
The financial resums of the subsidiary fof the period were".
Name
Income Expenditure Prof•Ulloss)
for the year
Net ass8ts
TREAT-NMD SeNces Ltd
2.812.148
(2.822.444Tr
110.2961
817.212
P•3e 30

Oor)J*Jn ETh¥e￿pe ID". BLf8E02F.F7B>8Th803749811C690562
TREAT-NMD Alliance Ltd
Note5 to the financial statements
Period ended 31 December 2025
15. Debtovs
Group
2025
Group
2024
Charity
2025
Charity
2024
Trade debtors
Olher debtors
Prepayments and acenjed in￿￿
Deferred tsx
VAT recoverable
258.668 609.
2,373
226.841
3,307
41.987
15,000
10.000
532.032
15,249
28.271
5.726
563
796.426
884.476
30,250
38,834
16.
Croditors: arnounts falling due within one year
Group
2025
Group
2024
Charity
2025
Charity
2024
Trade creditors
Amounts owed to group urthrtakings
Other laxalKJn and So￿al wurty
Other creditors
Accruals and deferred income
119.591
174,332
750
169.631
76.884
15.241
38.780
7.621
499,798
28.955
12.282
805,203
358,626
665.790
1.020.772
92.125
529,007
Group
2025
Group
2024
Charity
2025
Charrty
2024
Deferied income at the beginning of the
peri¢xl
Resources deferred during the year
Amounts Teleased from prev￿￿$ perwjds
954,S33
1,296.Q72
1804.200)
294,327
954,533
{294,327}
358,626
358.626
{358.626)
1.446.405
954,533
358,626
PwJe 31

tlotJJswJfi Envelope ID.. 80c8EO2F.F7BM￿o037.E9&11C08OS62
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
17. Creditops: amounts falling due after more than one year
Group
2025
Group
2024
Accruals and deferred income
966,13S
149.330
A￿r￿al$ and deferred incorre relales lo a granl reeeipl receive(I during the periodtyear. which is
rin9fenced for future expenditure on the PaLaOln project and is held in a separate bank account.
18. Statement of funds
SlateTrient of funds- current year
Balance at
31
December
2025
Balance at 1
1 August
2024
Income Expenditure
Unrestricted funds
General Funds
837.146
2,636.407
{2,646.7031
826.850 .
Restrlcted funds
PaLaDln Proj
458.177
1458.1771
Total of funds
837.146
3.094.584
13.104.880)
826,850
Statement of funds - prior year
Balance at
Balance at
1 August Income las Expendrture 31 July 2024
2023
restaledl {as restated) las reslaledl
Unrestricted funds
General Fund5 (see note 4}
876.S10
2,364.244 {2.403,608)
837,146
Restrlcted funds
PaLaDln Pro1￿t (see rK>te 4}
114,807
1114,807)
Total of fund5
876,510
2,479,051
(2.518.415}
837.146
Page 32

Docusiw Fn¥eloF* ID.. BoceED2F.F7B3-89CA4037E9811C68D562
TREAT-NMD Alliance Ltd
Notes to the financlal statements
Period ended 31 December 2025
19. Analysis of net assets between funds
Analysis ol net assets between funds- current year
Unrestricted Restricted
fund5
funds
2025
2025
Total
funds
2025
Tangible fixed assets
Current assets
Creditors due wthin one year
Cre￿￿orS due in more than one
18,227
1,474.413
1665,7901
18,227
2.440,548
1665,790
1966,1351
966,135
I￿.135)
Total
826,850
826,850
Analysis of net assets between funds - prior year
Unrestricted
funds
2024 las
reslaled)
RestrKled
funds
2024 las
restated)
Total
funds
2024 (as
restated)
Tangible fixed assets
Current assets
Creililors due within one year
Creditors due in more than one year
6.596
1,851.322
11.020.772)
6.596
2,000,652
11,020.7721
1149.3301
149.330
1149.3301
Total
837.146
837,146
The pric* year figures for current assets arKI creditors due in more than one year. as shown above, have
been reslaled lo recognise £149,330 of grant monies wthin restrKtsd fLtnds, rather than unrestrided
fund5 as previously reported Isee note 4 for further details}.
Page 33

OotsJsvJn En¥elope ID.. 8OC8ED2F-F7BM9CA-8037.E9811WD
TREAT-NMD Alliance Ltd
Notes to the financial statements
Period ended 31 December 2025
Reconciliation of net movemenl in funds to net cash flow from operaling a¢ti¥itbes
Group
17 months
Group
to 31 12 months
December
10 31 July
2025
2024
Nel expendilure for the perK#Jfyear las per SL*ement (rf Finaneial Activities
110,2961
139,3641
Ad5ustments for.
DepreCiat￿n charge5
Decrea$el{increase} in debtors
Increase in creditors
3.201
88.051
461,822
4,262
{298,6621
729,070
Net cash from operatlng acllvllies
$42,778
395,306
21. Analys55 of cash and Cash equlvalents
Group
2025
Group
2024
Cash in hand
1.644.122
1,116,176
The cash balance of £1.644.122 inckKle5 8 granl ￿elp1 of £966,135 (2024.. £149.3301 which is
ringfenced for fulure eXPendrtu￿ and is included in deferred income.
21 Analysls of changes in nel debt
At31
December
2025
At I Au9USt
2024 Cash flows
Cash at bank and in hand
1,116.176
527.946
1,644.122
23. Pension commitments
The group operates a defined contributions pension scheme. The assets of the scheme are held
separalety from those of the group in an independent￿ administered fund. The pension cost charge
represents contributions payable by the c¢)mpany lo the fund and amounted 10 £62,69212024." £36,873).
Contributions lotalling £7,621 12024.. £3,467) were payable lo the fund al the balance sheet dale and are
included in cred((ots.
Page 34

DocU￿9n Envd¢pe ID.. Bt(8ED2F_F￿89CAW37￿811c6fjOS62
TREAT-NMD Alliance Ltd
Notes to the financlal statements
Period ended 31 December 2025
Relat•d party transactlons
During the perwjd honoraiium payTnents totalling £nil {2024.. £734) were paid to J Dowling. ex- tru$tee. for
attendance al TACT meetsngs.
During the period reimbursements totalliNJ £1.94912024'. £nif) were paid to K Wagner. chair and trustee,
for travel.
During the year honorarium payments lotslling £nil {2024: £500) were paKI to A Oe Luca, ex- trustee, for
attendance at TACT meetings.
During the perio￿. payments of £nil (2024.. £27.2321 were paid lo Muscular Dystrophy Association USA.
charity in whKh S Hesterlee, a director of Treal-NMD Servtts Lwnited, has significant influence. in
relation lo a gene therapy mastefclass.
During the period, payments totalling £1,581 12024." £7.0001 were paKI to Newcastle University. an
organisation wlh signffieanl influence. in relalKJn to honorariums to conlribulors and project participation
fees.
Page 35